175136-20-6 Usage
Uses
Used in Pharmaceutical Industry:
4-(3,4-DICHLOROBENZYLOXY)-3-NITROBENZALDEHYDE is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the formation of complex molecular structures. Its presence in the manufacturing process aids in the creation of new and existing drugs, enhancing their efficacy and potential applications in medicine.
Used in Organic Synthesis:
In the field of organic synthesis, 4-(3,4-DICHLOROBENZYLOXY)-3-NITROBENZALDEHYDE is employed as a building block for more complex molecules. Its unique functional groups allow for versatile reactions and the formation of a wide range of chemical compounds, making it a valuable component in the synthesis of various organic compounds.
Used in Research and Development:
4-(3,4-DICHLOROBENZYLOXY)-3-NITROBENZALDEHYDE is also utilized in research and development due to its unique properties and potential applications across various industries. Its exploration in scientific studies contributes to the discovery of new uses and the enhancement of existing ones, further expanding its relevance in the chemical and pharmaceutical sectors.
Check Digit Verification of cas no
The CAS Registry Mumber 175136-20-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,5,1,3 and 6 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 175136-20:
(8*1)+(7*7)+(6*5)+(5*1)+(4*3)+(3*6)+(2*2)+(1*0)=126
126 % 10 = 6
So 175136-20-6 is a valid CAS Registry Number.
InChI:InChI=1/C14H9Cl2NO4/c15-11-3-1-10(5-12(11)16)8-21-14-4-2-9(7-18)6-13(14)17(19)20/h1-7H,8H2
175136-20-6Relevant academic research and scientific papers
Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1558
Takano, Rieko,Yoshida, Masao,Inoue, Masahiro,Honda, Takeshi,Nakashima, Ryutaro,Matsumoto, Koji,Yano, Tatsuya,Ogata, Tsuneaki,Watanabe, Nobuaki,Hirouchi, Masakazu,Kimura, Takako,Toda, Narihiro
, p. 5546 - 5565 (2015/11/11)
GPR40 agonists stimulate insulin secretion only under the presence of high glucose concentration. Based on this mechanism, GPR40 agonists are believed to be promising novel insulin secretagogues with low risk of hypoglycemia. The optimizations of 3-aryl-3-ethoxypropanoic acids were performed to improve in vitro activity. We discovered compound 29r (DS-1558), (3S)-3-ethoxy-3-(4-{[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]oxy}phenyl)propanoic acid, which was confirmed to have an enhancing effect on glucose-dependent insulin secretion after intravenous glucose injection in SD rats.
CARBOXYLIC ACID COMPOUND
-
Page/Page column 48, (2011/04/14)
To find a therapeutic agent and/or a preventive agent for diabetes mellitus or the like having excellent activity and safety. A compound represented by the following general formula (I), or a pharmacologically acceptable salt thereof. In the formula, X re
